These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38703566)

  • 1. Chemokine‑ and chemokine receptor-based subtypes predict prognosis, immunotherapy and chemotherapy response in colorectal cancer patients.
    Zhu W; Zhao S; Cheng X; Wu C; Liu Z; Huang J
    Int Immunopharmacol; 2024 Jun; 134():112172. PubMed ID: 38703566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemokine- and chemokine receptor-based signature predicts immunotherapy response in female colorectal adenocarcinoma patients.
    Zhu W; Wu C; Hu S; Liu S; Zhao S; Zhang D; Qiu G; Cheng X; Huang J
    Sci Rep; 2023 Dec; 13(1):21358. PubMed ID: 38049474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated analysis reveals a novel 5-fluorouracil resistance-based prognostic signature with promising implications for predicting the efficacy of chemotherapy and immunotherapy in patients with colorectal cancer.
    Hou Y; Zhang F; Zong J; Li T; Gan W; Lv S; Yan Z; Zeng Z; Yang L; Zhou M; Zhao W; Yang M
    Apoptosis; 2024 Aug; 29(7-8):1126-1144. PubMed ID: 38824480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational identification and clinical validation of a novel risk signature based on coagulation-related lncRNAs for predicting prognosis, immunotherapy response, and chemosensitivity in colorectal cancer patients.
    Zhang F; Zhang R; Zong J; Hou Y; Zhou M; Yan Z; Li T; Gan W; Lv S; Yang L; Zeng Z; Zhao W; Yang M
    Front Immunol; 2023; 14():1279789. PubMed ID: 37928532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma.
    Fan T; Liu Y; Liu H; Wang L; Tian H; Zheng Y; Zheng B; Xue L; Tan F; Xue Q; Gao S; Li C; He J
    Cancer Immunol Immunother; 2021 Dec; 70(12):3651-3667. PubMed ID: 33977344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An immune landscape based prognostic signature predicts the immune status and immunotherapeutic responses of patients with colorectal cancer.
    Li M; Li W; Yang X; Wang H; Peng Y; Yin J; Lu Y; Liu L; Shang J; Zhao Q
    Life Sci; 2020 Nov; 261():118368. PubMed ID: 32888940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mitophagy-related gene signature associated with prognosis and immune microenvironment in colorectal cancer.
    Zhang C; Zeng C; Xiong S; Zhao Z; Wu G
    Sci Rep; 2022 Nov; 12(1):18688. PubMed ID: 36333388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel hypoxia- and lactate metabolism-related molecular subtyping and prognostic signature for colorectal cancer.
    Huang A; Sun Z; Hong H; Yang Y; Chen J; Gao Z; Gu J
    J Transl Med; 2024 Jun; 22(1):587. PubMed ID: 38902737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A CLRN3-Based CD8
    Gong Z; Huang X; Cao Q; Wu Y; Zhang Q
    Biomolecules; 2024 Jul; 14(8):. PubMed ID: 39199281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel prognostic alternative splicing events in colorectal Cancer: Impact on immune infiltration and therapy response.
    Xiao Y; Gao L; Zhao X; Zhao W; Mai L; Ma C; Han Y; Li X
    Int Immunopharmacol; 2024 Sep; 139():112603. PubMed ID: 39043103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of an immune prognostic signature in colorectal cancer.
    Li M; Wang H; Li W; Peng Y; Xu F; Shang J; Dong S; Bu L; Wang H; Wei W; Hu Q; Liu L; Zhao Q
    Int Immunopharmacol; 2020 Nov; 88():106868. PubMed ID: 32771948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of the relationship between ubiquitin-specific protease 21 (USP21) and prognosis, tumor microenvironment infiltration, and therapy response in colorectal cancer.
    Nie H; Yu Y; Wang F; Huang X; Wang H; Wang J; Tao M; Ning Y; Zhou J; Zhao Q; Xu F; Fang J
    Cancer Immunol Immunother; 2024 Jun; 73(8):156. PubMed ID: 38834869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel TGF-β-Related Signature for Predicting Prognosis, Tumor Microenvironment, and Therapeutic Response in Colorectal Cancer.
    Tao B; Yi C; Ma Y; Li Y; Zhang B; Geng Y; Chen Z; Ma X; Chen J
    Biochem Genet; 2024 Aug; 62(4):2999-3029. PubMed ID: 38062276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis of colorectal cancer, prognostic index of immunogenic cell death associated genes in response to immunotherapy, and potential therapeutic effects of ferroptosis inducers.
    Lei M; Xiao M; Long Z; Lin T; Ding R; Quan Q
    Front Immunol; 2024; 15():1458270. PubMed ID: 39372411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an anoikis-related gene signature and prognostic model for predicting the tumor microenvironment and response to immunotherapy in colorectal cancer.
    Li C; Weng J; Yang L; Gong H; Liu Z
    Front Immunol; 2024; 15():1378305. PubMed ID: 38779664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptomic correlates of cell cycle checkpoints with distinct prognosis, molecular characteristics, immunological regulation, and therapeutic response in colorectal adenocarcinoma.
    Wang H; Wang W; Wang Z; Li X
    Front Immunol; 2023; 14():1291859. PubMed ID: 38143740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of an immune predictive model and identification of TRIP6 as a prognostic marker and therapeutic target of CRC by integration of single-cell and bulk RNA-seq data.
    Liu W; Luo X; Zhang Z; Chen Y; Dai Y; Deng J; Yang C; Liu H
    Cancer Immunol Immunother; 2024 Mar; 73(4):69. PubMed ID: 38430268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical assessment and identification of immuno-oncology markers concerning the 19-gene based risk classifier in stage IV colorectal cancer.
    Lee JL; Roh SA; Kim CW; Kwon YH; Ha YJ; Kim SK; Kim SY; Cho DH; Kim YS; Kim JC
    World J Gastroenterol; 2019 Mar; 25(11):1341-1354. PubMed ID: 30918427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
    Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
    Front Immunol; 2022; 13():951455. PubMed ID: 36189298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
    Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
    Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.